Speech by the President of the Republic at the Curie Institute.

France Emmanuel Macron · President of France

16 May 2023 · Institut Curie

Context
Macron addressed researchers, doctors, patients, and officials at the Curie Institute in Paris on May 16, 2023, to announce major health innovation investments under the France 2030 plan.
Main themes
Cancer research and oncology, health innovation policy, France 2030 investment plan, clinical and fundamental research integration, French healthcare model, medical advances and treatment access, health startups and industry investment, digital health, biotherapies, research funding and reinvestment, pandemic lessons, talent attraction and competitiveness
Duration
~24 min
73rd percentile
Words
2,824
73rd percentile
Sentences
96
61st percentile
Readability
39
35th percentile
Grade
15.0
76th percentile
Syntax
3.31
83rd percentile
Vocabulary
2.26
64th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 42%42%
  • Social 23%23%
  • Ceremonial 16%16%
  • Technological 15%15%
  • Institutional 4%4%
  • Geopolitical 1%1%
  • Environmental 0%0%
  • Not in focus 0%

96 sentences in 33 paragraphs

Ladies and gentlemen ministers,

Mr. Prefect,

Mr. Deputy,

Mr. Mayor,

Madam Director General of the ARS,

Ladies and gentlemen presidents and directors of Research Institutes and University Hospital Institutes,

Ladies and gentlemen researchers, doctors, technicians, students, entrepreneurs, industrialists, and of course, dear patients,

First of all, I want to express the great happiness my wife and I feel to be among you and with our three ministers. The announcements I am about to make are the result of work that recognizes your commitment to everyone here. But the few moments we have spent among your teams and with your patients remind us of two things.

The first is that these are human adventures. Caring for and looking after our fellow citizens, as well as the women and men who come here to receive care and build their future. I truly want to thank you for the time, energy, and talents you dedicate to researching, healing, and caring for them with great humanity. This is the foundation; the rest is secondary, and it is about giving you the means to succeed.

The second thing, and I believe the Curie Institute shows this so well, is the strength of the French model, which is the marriage, intimacy, and circulation of knowledge between clinical practice, fundamental research, and applied research. This ongoing circulation is essential and makes us stronger. It first shows how care is nourished by research and vice versa, but it also allows us, I believe, to never lose sight of the importance of fundamental research, which we also mentioned a moment ago. The entire history of medical advances has shown how much it is a collective story, and we experienced this again when we faced the pandemic together, and I believe this is one of the collective lessons, I would not say we learned at that time, but which was reminded to us.

So in this area, France has experienced and continues to experience great successes, inspired obviously by pioneering figures, by many of you, and I salute all the great researchers and clinicians present here, by our organizations, research laboratories, our universities, and top-level hospitals, starting with the one we are in, which has made French oncology a global leader. But we also know that we have allowed weaknesses to settle in, inherited from several years of lack of investment, sometimes of compartmentalization, and because we have also allowed international competition to attract other talents, to move faster on certain innovations.

It is strong, I would say, from this observation, because we also experienced the pandemic, that we decided in June 2021 to launch the Health Innovation plan within France 2030, providing massive resources: 7.5 billion euros in this framework; regulatory means to facilitate access to innovative treatments with, for example, the exceptional early access device and now the small revolution of direct access, published these days in the Official Journal. And for all the times when shorter deadlines can be applied, we know that these are treatments that arrive faster and with more pragmatism. We are doing what we said; it is a major tool for attractiveness for our industrialists. We saw it again yesterday, where more than one billion euros was invested with GSK and Pfizer over several years by these two major industrial players because we were able to adapt our rules, simplify them, and fundamentally have an attractiveness policy that is essential.

These are structural means with the launch of the Health Innovation Agency, and I really want to thank the Director General, all the teams who have already worked hard and who are working on accelerating clinical trials, supporting innovative projects, or with third-party experimentation sites in digital health, where we know we still need to accelerate, but which have already made significant progress. And then, these are financial means, by promoting investment in our startups, SMEs, and major players, at the Paris Health Campus or elsewhere, often with the support of Bpifrance, but also by seeking, as we know, private funds with what we called the Tibi initiative, which has essentially worked, as we know, Bruno BONNELL can testify, in the field of health, which is the one that has attracted the most private funding through this channel. We also planned resources to strengthen our research in biology and health, by increasing the massive reinvestment initiated with the research law, which I have come to present to you today.

So, there have been 400 million euros invested to launch research programs, to develop digital health and innovative biotherapies, to fight against cancers and chronic diseases, or to understand and treat endometriosis. And no less than 7 programs led by INSERM. I really want to salute, here too, its action. INRAE and INRIA have also been launched, and we now need to accelerate them. And then, we have 100 million euros that were planned by this plan, the details of which are presented today; the ministers will return to reinforce our cohorts and our biology infrastructures with projects, also financed throughout France. From the P4 laboratory in Lyon to the proteomics platforms in Strasbourg, through the metabolic platforms in Toulouse and France Genomics in Evry. These are essential platforms to provide high-level technological and methodological support to French research teams. And here too, we had made this commitment regarding the infrastructures that will be deployed as part of the Health Innovation plan. It is today that these resources are officially announced, so you see, in fact, for the past 18 months, almost two years, we have accelerated these investments that have come, in a way, above the programming law, the multiannual law for research and higher education, to give more strength to our health research.

But today, I wanted to announce that our commitment will amplify, and through three categories of announcements, also give the means to several teams present here, particularly to you, to go further and stronger.

First, we will support 10 new university hospital institutes in Bordeaux with the VBHI project, Nice with the RespirERA project, Montpellier with the Immun4Cure project, Lyon with the Everest project, and finally in Île-de-France with the Prisme, InnovAND, Reconnect, Prometheus, and ThéMA II projects, and naturally, the Curie project on women's cancer, which will be a laureate. For all these projects, between 20 and 40 million euros will be provided in funding. I want to salute all those, researchers, clinicians, technicians, who have contributed to this very strong dynamic, with also many partner companies such as Janssen, Roche, Dassault Systèmes, Withings, and several other startups that we discussed together and who are your partners, some of whom we hope to bring back to France; we are working hard on this.

These centers concern neurovascular, pulmonary, autoimmune diseases, oncology, pediatrics, or aging and represent tremendous hopes for our patients. They are not only a place for training top professionals but also fields for experimentation, new modalities of care and prevention, as well as pools of ambitious partnerships between industrialists, researchers, and clinicians, as I mentioned. And since we also believe in emergence, we will support two emerging IHU projects in Nancy on inflammatory bowel diseases and in Toulouse on age-related diseases, which will broaden the spectrum of issues addressed. These will be somewhat more modest tickets and projects that will be supported in their growth, but on which, moreover, in light of independent and international juries, it was deemed pertinent to make an investment and help this emergence. All these projects constitute a total funding of a little more than 300 million euros.

In addition, and this is the second category of announcements, we must continue to take a step forward, and that is why we will create 5 bioclusters of global dimension, fully part of this health innovation plan that I just mentioned.

The first project on oncology in Saclay was announced at the end of last year and will be complemented by a project in Marseille and a new project on the brain in Paris. The Brain & Mind project will indeed allow us, in Paris, a considerable acceleration in research on the brain and neuroscience, where we already have considerable strengths. It relies on historical IHUs and on projects and others that already had great maturity, with José-Alain SAHEL and many others. Thanks to this broad, open, entrepreneurial ecosystem, this consortium will have the credibility and international reach necessary to attract all talents beyond borders.

In Marseille, it is a project that will aim to catalyze the development of a global ecosystem in the field of immunology by bringing together leading players to accelerate the development of drug candidates against cancer, autoimmune diseases, and infectious diseases from the design and optimization of the drug candidate to the clinic. With, there too, laboratories of excellence, therapeutic startups, and several large groups around the table. These projects are ready, must be launched quickly because they cannot wait, and they are fully mature. Therefore, the funding will be finalized in the coming days so that they can start at full speed.

To gain efficiency, we will also structure Bioclusters on biotherapies and emerging infectious diseases, which are two of our priorities. There are two projects that will also be supported to structure them further, but which are selected among the five Bioclusters: the Lyon project on emerging diseases, also strengthening our research on vaccines in France, also integrating the projects of vaccinology centers currently under consideration, including those led by the CEA, Inserm, and the Pasteur Institute. Here too, we must succeed in this strategic project by coming together around a coherent and unified project whose epicenter will be the Lyon project. I note it and mention it here: it must mature, particularly on the business model, as the jury said, but it is a project that has been recognized as scientifically excellent and thus is selected among the Bioclusters.

And then the fifth, on biotherapies around AFM-Téléthon. In this area, which opens major perspectives for patients and where the AFM teams are at the forefront with gene and cell therapies, but also with production. And so, I hope that our orientations in three months will allow these two projects, which are labeled today, to fully finalize their projects, to respond to the requests made by the jury. They will complement the three other projects I mentioned: Saclay, Marseille, and Brain & Mind, which are fully mature.

These five projects are therefore our five Bioclusters on which we will invest 400 million euros. And so, you see, it is a massive investment from the Nation, but with a particularity that I want to emphasize, which is that local authorities will also come alongside the State to invest with sometimes, and often, significant amounts. And industrialists are committed to co-financing these projects by more than 100, even 200%. This means that this investment I am talking about from the State will be complemented by investments from local authorities in many cases, but above all will be multiplied by private actors, which will allow us to have amounts, you see well, that will far exceed one billion and one and a half billion on these five Bioclusters, whether they are large or small, French or foreign. It is a sign that many major players believe in our science, in our research.

It is also a major sign of our attractiveness, of our reindustrialization, and of the fact that we are heading in the right direction. By doing so, these five Bioclusters, just like the IHUs I mentioned, demonstrate that it is outdated to oppose public and private in this matter and to force people to choose between an investment, between fundamental research and technological research, between public and private. They fertilize each other; I was still trying to explain this to some of our compatriots.

It is because we are making reforms that we are able to reinvest in the country, to reindustrialize, and to be collectively richer, that we can reinvest in the public sector and in what is not profitable. It is by creating more synergies between public and private actors that we also create projects that allow for this dynamic. I believe that it is at the same time quite fruitful and that it will allow us, in any case, to move forward faster.

Building on this new dynamic, and this is the third announcement I wanted to make among you, we will be launching in the coming weeks one of the important actions of this health strategy. We know that to become and remain a welcoming place for the best global scientists, we must also compete in the talent race. That is why we will offer the best researchers the opportunity to pursue or launch large-scale projects in France with the creation of around fifty chairs of excellence in biology and health, which are part of our higher education and research strategy, with very attractive resources. Up to 2 million euros per chair of excellence are thus planned.

The initiative will be launched in the coming days, with a very high-level jury that I salute, which will be chaired by Professor FISCHER and Professor CONTI, and which will allow for the selection of these researchers, to define this fifty chairs of excellence projects in biology and health, with a lot of flexibility, including on the timeline, to allow for responses, if I may say, that will be tailored and that will help attract our talents. We want to train more, we want to retain the talents we train, and we also want to attract talents from around the world. We must continue to improve our attractiveness and clarity to do better. These are the three major announcements I wanted to make as part of this strategy.

I would like, to conclude my remarks, to complement this with a few perspectives and, if I may, say, lines of flight that I wanted to open. First, we see that in the face of silo logic, the time has come to work towards a more unified biomedical research, better funded, by breaking down funding barriers, shortening timelines, and betting on the responsibility of the actors. We must continue to strengthen Inserm, whose new president, Professor Didier SAMUEL, I salute, to promote biomedical research in France and internationally and to assist in its structuring. Regarding clinical trials, whether academic or industrial, we need to modernize, accelerate our processes, and draw inspiration from foreign models, obviously respecting ethical principles.

But we know that we can do better. And to carry out these transformations, I wish for the Minister of Higher Education and Research, the Minister of Health and Prevention, and the Minister Delegate for Industry, with the help of the Health Innovation Agency and the France 2030 Mission, to hold consultations with all concerned actors that should lead to an action plan in the next six months for a more unified and effective biomedical research.

Similarly, we need to work on strengthening the industrialization of the technological process in health and biotechnology, and if I may say, this is the downstream phase of what I was referring to. On many projects, including those we have funded and supported in recent years, we have too often seen the industrial process then develop elsewhere, sometimes because we are too slow, too complex, and do not have the most competitive conditions for the development of the technological process. This is a collective loss of opportunity because we finance research, we finance the initial developments in our country, and we see actors then grow in other countries, where they could fertilize the research and innovation ecosystems that are ours and help us develop solutions. Here too, I hope that the ministers can, within six months, provide us with concrete proposals.

These projects, as you can see, outline the face of France in 2030, which is the one we want and which, I believe, is good for the country, one that does not forget our values and principles of humanism, ethics, and attention to others; but which, embracing the challenges of the world that are opening up, deciding to place France at the heart of all technological innovations, gives itself the means to have fundamental research, applied research, technological innovation, and collaboration between public and private actors at the highest international standards, and allows for the recognition of the place of the talents we train by giving them more freedom and more resources and enabling them to work better collectively.

These are the few words I came to share with you, ending by thanking you, as I began to do again, for the time and passion you put into your work. Because I know that the lives you lead are lives of passion where nights and days do not count when it comes to finding or healing. I wanted to thank you for that because that is the true treasure.

Long live the Republic and long live France!